TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients with A1c ≤9%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with BP <140/90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with LDL <130 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean corneal apex temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of uptake and intensity of SUV in ipsilateral axillary lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Platelet reactivity <40 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel motions per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hfPGA score of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of visibility aids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zygapophyseal joint space width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zygapophyseal joint space area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zygapophyseal joint space density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of contrast agent in liver MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP indicators as a surrogate screening marker of Insulin Resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RULA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of laparoscopic sutures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Taste preference for unfrozen vs frozen sushi
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FSFI total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lubrication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: burnout
Endpoint domain: Adverse events/effects
Primary endpoint: Victorian Institute of Sports Assessment‐Achilles improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACE2 mRNA expression in monocyte-derived macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Short Opiate Withdrawal Syndrome total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores in the Huskisson's analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of coronary CT angiography in detection of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in obesity-related plasma metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in cardiometabolic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PC density reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MSCL improvements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of patients achieving complete remission (CR) and very good partial remission (VGPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory clinical effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of skills to support evidence-based social care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severity of morphine-induced pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: change in serum potassium over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new brain infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: General Cognitive Index of the McCarthy Scales of Children's Abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peabody Picture Vocabulary Test-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting Stress Index-Short Form Total Stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall mortality after discharge
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: emergence delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postanesthesia length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: self-reported control over alcohol-related thoughts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cue-elicited activation in the OFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LDL-C/HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean plasma nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exhaled CO boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fear of negative evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incremental cost per additional survivor without BPD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of severe mucositis and dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of mucositis and dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: perception of physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean duration of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of irregular bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: duration of irregular bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean total treatment costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic and pharmacodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality associated with high levels of VWF, fibrinogen and FVIII:C
Endpoint domain: Mortality/survival
Primary endpoint: Development of venous thrombotic event (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: symptom relief at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C less than 8%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood pressure less than 140/90 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight loss greater than 10 lb (4.5 kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cosmetic effect
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease control rate (DCR) at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: primary renal composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: positive rate of AsAb (IgM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total perioperative fluid received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colloid osmotic pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall expenditure on food
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative percentage of tolerance to CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with controlled cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal butyrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total fecal SCFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for repeat target vessel revascularization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean root coverage percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean keratinized tissue width (POSTKT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting pain score 3 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-month attendance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Antibodies to histone (H2A‐H2B)‐DNA complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical SF-12 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental SF-12 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EPER rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute OXLIPN requiring prolongation of oxaliplatin infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of n-3 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cutaneous phototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: No hope for the future
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling down, depressed or hopeless
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in depth of knowledge of targeted cross-curriculum words
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: first pass success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of carotid puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients free of pain and inflammatory symptoms at D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain scores versus baseline after 3 days' treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain and/or fever at 3 to 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LLS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute mountain sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving 90 degrees flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients able to discontinue prednisone without a disease flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of smoking and bed‐sharing as SUDI risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regular bed-sharing at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Pēpi-Pods at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PIVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Activity level of vitamin K‐dependent coagulation factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: heavy drinking occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum reticulocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the effect curve to the last observation (AUEC(0-last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intentions to use condoms and contraceptives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in UPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Daily Living skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of multiorgan failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average HRV decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RMSSD decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cutaneous blood perfusion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Major adverse cardiovascular event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restenosis rate of the ostium of side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area of periincisional hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent second- to third-degree AV block
Endpoint domain: Adverse events/effects
Primary endpoint: Time required for root-end cavity preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Healing rates of erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relief of reflux symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Engagement with gout app
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge/understanding of gout
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Beliefs regarding severity of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: range of femoral component rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior condylar cut thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intercompartmental force difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma FGF19 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Extrapyramidal symptoms (EPS) profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRA patency at baseline coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median hair-free intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual colonic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: child aggressive behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of allergen-IgE binding to B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentric force production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: subsequent surgery rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean improvement in I-QOL total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: increase in fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduced intake to less than 30% calories from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improved performance of dietary behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood product requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interoceptive sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily doses of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of unexpected hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Low-density lipoprotein-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HgBA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: body mass index z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of voids daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom specific quality of life measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: achieved dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination rate for major FD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: correct mental health triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin leakage from the skin
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in dietary anamnesis performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-year overall survival rates
Endpoint domain: Mortality/survival
Primary endpoint: locoregional recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the insulin concentration-time curve (AUC) from 0 to 90 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to maximum serum insulin concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum insulin concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dentine hypersensitivity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of postoperative nausea and vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tyrosine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alanine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenylalanine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histidine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean TAED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of TNF‐alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stress response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of treatment failure for AL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of treatment failure for DP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain cessation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes